Lucca Tamara Alves Carretta, Ocilio Ribeiro Gonçalves, Mariana Lee Han, Kenzo Ogasawara Donato, Yasmin Picanço Silva, Luciano Falcão, Rian Barreto Arrais Rodrigues de Morais, Nicole Baptista de Oliveira, Mariana Letícia de Bastos Maximiano, Ahmet Günkan
{"title":"LVIS versus enterprise stents for stent-assisted coiling of intracranial aneurysms: a systematic review and meta-analysis.","authors":"Lucca Tamara Alves Carretta, Ocilio Ribeiro Gonçalves, Mariana Lee Han, Kenzo Ogasawara Donato, Yasmin Picanço Silva, Luciano Falcão, Rian Barreto Arrais Rodrigues de Morais, Nicole Baptista de Oliveira, Mariana Letícia de Bastos Maximiano, Ahmet Günkan","doi":"10.1007/s00234-025-03748-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review and meta-analysis aimed to compare the clinical and angiographic outcomes of the LVIS versus the Enterprise stent for the treatment of intracranial aneurysms (IAs).</p><p><strong>Methods: </strong>Eligible studies were extracted from PubMed, Scopus, and Embase comparing LVIS/Enterprise. Data on angiographic occlusion rates, neurological deficits, in-stent stenosis, hemorrhagic complications, thromboembolic complications and aneurysm recanalization were analyzed with statistical methods.</p><p><strong>Results: </strong>5 observational studies (912 patients: 457 treated with LVIS and 455 with Enterprise) were analyzed. LVIS was linked to a significantly lower likelihood of Raymond-Roy Occlusion Classification (RROC) Class 3 (RR 0.30; 95% CI 0.13-0.71; I²=0%) and aneurysm recanalization (RR 0.38; 95% CI 0.18-0.82; I²=0%). No statistically significant differences were found between the two groups regarding mRS 0-2, RROC Class 1 or 2, or the incidence of neurological deficits, in-stent stenosis, hemorrhagic or thromboembolic events.</p><p><strong>Conclusion: </strong>LVIS and Enterprise demonstrate safety and efficacy in the endovascular management of IAs. LVIS may provide improved angiographic outcomes by lowering the risk of recurrence and incomplete occlusion. These findings support its potential advantage in treating complex aneurysms. Further confirmation through randomized controlled trials (RCT) is needed.</p>","PeriodicalId":19422,"journal":{"name":"Neuroradiology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroradiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00234-025-03748-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This systematic review and meta-analysis aimed to compare the clinical and angiographic outcomes of the LVIS versus the Enterprise stent for the treatment of intracranial aneurysms (IAs).
Methods: Eligible studies were extracted from PubMed, Scopus, and Embase comparing LVIS/Enterprise. Data on angiographic occlusion rates, neurological deficits, in-stent stenosis, hemorrhagic complications, thromboembolic complications and aneurysm recanalization were analyzed with statistical methods.
Results: 5 observational studies (912 patients: 457 treated with LVIS and 455 with Enterprise) were analyzed. LVIS was linked to a significantly lower likelihood of Raymond-Roy Occlusion Classification (RROC) Class 3 (RR 0.30; 95% CI 0.13-0.71; I²=0%) and aneurysm recanalization (RR 0.38; 95% CI 0.18-0.82; I²=0%). No statistically significant differences were found between the two groups regarding mRS 0-2, RROC Class 1 or 2, or the incidence of neurological deficits, in-stent stenosis, hemorrhagic or thromboembolic events.
Conclusion: LVIS and Enterprise demonstrate safety and efficacy in the endovascular management of IAs. LVIS may provide improved angiographic outcomes by lowering the risk of recurrence and incomplete occlusion. These findings support its potential advantage in treating complex aneurysms. Further confirmation through randomized controlled trials (RCT) is needed.
期刊介绍:
Neuroradiology aims to provide state-of-the-art medical and scientific information in the fields of Neuroradiology, Neurosciences, Neurology, Psychiatry, Neurosurgery, and related medical specialities. Neuroradiology as the official Journal of the European Society of Neuroradiology receives submissions from all parts of the world and publishes peer-reviewed original research, comprehensive reviews, educational papers, opinion papers, and short reports on exceptional clinical observations and new technical developments in the field of Neuroimaging and Neurointervention. The journal has subsections for Diagnostic and Interventional Neuroradiology, Advanced Neuroimaging, Paediatric Neuroradiology, Head-Neck-ENT Radiology, Spine Neuroradiology, and for submissions from Japan. Neuroradiology aims to provide new knowledge about and insights into the function and pathology of the human nervous system that may help to better diagnose and treat nervous system diseases. Neuroradiology is a member of the Committee on Publication Ethics (COPE) and follows the COPE core practices. Neuroradiology prefers articles that are free of bias, self-critical regarding limitations, transparent and clear in describing study participants, methods, and statistics, and short in presenting results. Before peer-review all submissions are automatically checked by iThenticate to assess for potential overlap in prior publication.